{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:34:58Z","timestamp":1785803698986,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC8-2020 ext (Eramo-Lucarelli); FFC8-2021 (Lucarelli-Eramo)"],"award-info":[{"award-number":["FFC8-2020 ext (Eramo-Lucarelli); FFC8-2021 (Lucarelli-Eramo)"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004588","name":"Istituto Pasteur-Fondazione Cenci Bolognetti","doi-asserted-by":"publisher","award":["2020 (Lucarelli)"],"award-info":[{"award-number":["2020 (Lucarelli)"]}],"id":[{"id":"10.13039\/501100004588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is caused by defects of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR-modulating drugs may overcome specific defects, such as the case of Trikafta, which is a clinically approved triple combination of Elexacaftor, Tezacaftor and Ivacaftor (ETI) that exhibited a strong ability to rescue the function of the most frequent F508del pathogenic variant even in genotypes with the mutated allele in single copy. Nevertheless, most rare genotypes lacking the F508del allele are still not eligible for targeted therapies. Via the innovative approach of using nasal conditionally reprogrammed cell (CRC) cell-based models that mimic patient disease in vitro<jats:italic>,<\/jats:italic> which are obtainable from each patient due to the 100% efficiency of the cell culture establishment, we theratyped orphan CFTR mutation L1077P. Protein studies, Forskolin-induced organoid swelling, and Ussing chamber assays congruently proved the L1077P variant function rescue by ETI. Notably, this rescue takes place even in the context of a single-copy L1077P allele, which appears to enhance its expression. Thus, the possibility of single-allele treatment also arises for rare genotypes, with an allele-specific modulation as part of the mechanism. Of note, besides providing indication of drug efficacy with respect to specific CFTR pathogenic variants or genotypes, this approach allows the evaluation of the response of single-patient cells within their genetic background. In this view, our studies support in vitro guided personalized CF therapies also for rare patients who are nearly excluded from clinical trials.<\/jats:p>","DOI":"10.1186\/s12931-023-02516-0","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T18:02:18Z","timestamp":1694023338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["L1077P CFTR pathogenic variant function rescue by Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in cystic fibrosis patient-derived air\u2013liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Stefania","family":"Lo Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Blacon\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina Maria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pigliucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Rachela","family":"Villella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Speranza","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Zollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero De","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Biffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Eramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"issue":"10059","key":"2516_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519\u201331.","journal-title":"Lancet"},{"issue":"6","key":"2516_CR2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","volume":"11","author":"V Scotet","year":"2020","unstructured":"Scotet V, L\u2019Hostis C, Ferec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020;11(6):589.","journal-title":"Genes (Basel)"},{"issue":"4","key":"2516_CR3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccm.2022.06.002","volume":"43","author":"KA McBennett","year":"2022","unstructured":"McBennett KA, Davis PB. Toward a broader understanding of cystic fibrosis epidemiology and its impact on clinical manifestations. Clin Chest Med. 2022;43(4):579\u201390.","journal-title":"Clin Chest Med"},{"issue":"10","key":"2516_CR4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","volume":"45","author":"PR Sosnay","year":"2013","unstructured":"Sosnay PR, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160\u20137.","journal-title":"Nat Genet"},{"issue":"8","key":"2516_CR5","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","volume":"4","author":"FAL Marson","year":"2016","unstructured":"Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med. 2016;4(8):e37\u20138.","journal-title":"Lancet Respir Med"},{"key":"2516_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102098","volume":"72","author":"O Laselva","year":"2022","unstructured":"Laselva O, et al. Small-molecule drugs for cystic fibrosis: where are we now? Pulm Pharmacol Ther. 2022;72: 102098.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"2516_CR7","doi-asserted-by":"crossref","first-page":"1iii","DOI":"10.1016\/j.ccm.2022.06.006","volume":"43","author":"CJ Britto","year":"2022","unstructured":"Britto CJ, Taylor-Cousar JL. Cystic fibrosis in the era of highly effective CFTR modulators. Clin Chest Med. 2022;43(4):1iii-xvi.","journal-title":"Clin Chest Med"},{"issue":"4","key":"2516_CR8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccm.2022.06.003","volume":"43","author":"AT Joynt","year":"2022","unstructured":"Joynt AT, Cutting GR, Sharma N. Genetics of cystic fibrosis: clinical implications. Clin Chest Med. 2022;43(4):591\u2013602.","journal-title":"Clin Chest Med"},{"issue":"Suppl 1","key":"2516_CR9","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jcf.2019.10.017","volume":"19","author":"MD Amaral","year":"2020","unstructured":"Amaral MD, et al. CFTR processing, trafficking and interactions. J Cyst Fibros. 2020;19(Suppl 1):S33\u20136.","journal-title":"J Cyst Fibros"},{"key":"2516_CR10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trsl.2015.04.008","volume":"168","author":"H Corvol","year":"2016","unstructured":"Corvol H, et al. Translating the genetics of cystic fibrosis to personalized medicine. Transl Res. 2016;168:40\u20139.","journal-title":"Transl Res"},{"issue":"3","key":"2516_CR11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27(3):424\u201333.","journal-title":"Mol Biol Cell"},{"issue":"19","key":"2516_CR12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"17","key":"2516_CR13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, et al. VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"issue":"10212","key":"2516_CR14","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138.","journal-title":"Lancet"},{"issue":"18","key":"2516_CR15","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","volume":"5","author":"G Veit","year":"2020","unstructured":"Veit G, et al. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor\u2013tezacaftor\u2013ivacaftor (Trikafta) combination. JCI Insight. 2020;5(18):e139983.","journal-title":"JCI Insight"},{"issue":"5","key":"2516_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","volume":"109","author":"K De Boeck","year":"2020","unstructured":"De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr. 2020;109(5):893\u20139.","journal-title":"Acta Paediatr"},{"issue":"4","key":"2516_CR17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1152\/ajplung.00465.2017","volume":"314","author":"M Harutyunyan","year":"2018","unstructured":"Harutyunyan M, et al. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Am J Physiol-Lung Cell Mol Physiol. 2018;314(4):1529\u201343.","journal-title":"Am J Physiol-Lung Cell Mol Physiol"},{"issue":"4","key":"2516_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jmedgenet-2016-103985","volume":"54","author":"V Terlizzi","year":"2017","unstructured":"Terlizzi V, et al. Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. J Med Genet. 2017;54(4):224\u201335.","journal-title":"J Med Genet"},{"issue":"3","key":"2516_CR19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/ijms23031437","volume":"23","author":"AS Ramalho","year":"2022","unstructured":"Ramalho AS, et al. Assays of CFTR function in vitro, ex vivo and in vivo. Int J Mol Sci. 2022;23(3):1437.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2516_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","volume":"18","author":"JP Clancy","year":"2019","unstructured":"Clancy JP, et al. CFTR modulator theratyping: current status, gaps and future directions. J Cyst Fibros. 2019;18(1):22\u201334.","journal-title":"J Cyst Fibros"},{"key":"2516_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102201","volume":"63","author":"MD Amaral","year":"2022","unstructured":"Amaral MD. Precision medicine for rare diseases: the times they are A-Changin\u2019. Curr Opin Pharmacol. 2022;63: 102201.","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 1","key":"2516_CR22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcf.2022.11.007","volume":"22 Suppl 1","author":"AS Ramalho","year":"2023","unstructured":"Ramalho AS, Amato F, Gentzsch M. Patient-derived cell models for personalized medicine approaches in cystic fibrosis. J Cyst Fibros. 2023;22 Suppl 1(Suppl 1):32\u20138.","journal-title":"J Cyst Fibros"},{"key":"2516_CR23","doi-asserted-by":"crossref","unstructured":"Sette G et al. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. Int J Cancer. 2018.","DOI":"10.1002\/ijc.31260"},{"key":"2516_CR24","doi-asserted-by":"crossref","unstructured":"Sette G et al. Theratyping cystic fibrosis in vitro in ALI-culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. Eur Respir J. 2021.","DOI":"10.1183\/13993003.00908-2021"},{"issue":"2","key":"2516_CR25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1164\/rccm.201507-1414OC","volume":"194","author":"CR Butler","year":"2016","unstructured":"Butler CR, et al. Rapid expansion of human epithelial stem cells suitable for airway tissue engineering. Am J Respir Crit Care Med. 2016;194(2):156\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2516_CR26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/humu.1380030329","volume":"3","author":"D Bozon","year":"1994","unstructured":"Bozon D, et al. Identification of four new mutations in the cystic fibrosis transmembrane conductance regulator gene: I148T, L1077P, Y1092X, 2183AA\u2013>G. Hum Mutat. 1994;3(3):330\u20132.","journal-title":"Hum Mutat"},{"issue":"Pt 1","key":"2516_CR27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1529-8817.2004.00130.x","volume":"69","author":"G Castaldo","year":"2005","unstructured":"Castaldo G, et al. Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population. Ann Hum Genet. 2005;69(Pt 1):15\u201324.","journal-title":"Ann Hum Genet"},{"key":"2516_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2119\/molmed.2014.00229","volume":"21","author":"M Lucarelli","year":"2015","unstructured":"Lucarelli M, et al. A genotypic-oriented view of CFTR genetics highlights specific mutational patterns underlying clinical macrocategories of cystic fibrosis. Mol Med. 2015;21:257\u201375.","journal-title":"Mol Med"},{"issue":"5","key":"2516_CR29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jmoldx.2017.06.002","volume":"19","author":"M Lucarelli","year":"2017","unstructured":"Lucarelli M, et al. A new targeted CFTR mutation panel based on next-generation sequencing technology. J Mol Diagn. 2017;19(5):788\u2013800.","journal-title":"J Mol Diagn"},{"issue":"6","key":"2516_CR30","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","volume":"41","author":"M Lopes-Pacheco","year":"2017","unstructured":"Lopes-Pacheco M, et al. Combination of correctors rescues CFTR transmembrane-domain mutants by mitigating their interactions with proteostasis. Cell Physiol Biochem. 2017;41(6):2194\u2013210.","journal-title":"Cell Physiol Biochem"},{"key":"2516_CR31","doi-asserted-by":"crossref","unstructured":"Lucarelli M et al. Simultaneous cycle sequencing assessment of (TG)m and Tn tract length in CFTR gene. Biotechniques. 2002; 32(3): 540\u20132, 544\u20137.","DOI":"10.2144\/02323st06"},{"issue":"2","key":"2516_CR32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ab.2006.03.022","volume":"353","author":"M Lucarelli","year":"2006","unstructured":"Lucarelli M, et al. A 96-well formatted method for exon and exon\/intron boundary full sequencing of the CFTR gene. Anal Biochem. 2006;353(2):226\u201335.","journal-title":"Anal Biochem"},{"issue":"9","key":"2516_CR33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1515\/CCLM.2011.604","volume":"49","author":"G Ferraguti","year":"2011","unstructured":"Ferraguti G, et al. A template for mutational data analysis of the CFTR gene. Clin Chem Lab Med. 2011;49(9):1447\u201351.","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"2516_CR34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/gt.2010.89","volume":"17","author":"C Auriche","year":"2010","unstructured":"Auriche C, et al. CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a single-step procedure. Gene Ther. 2010;17(11):1341\u201354.","journal-title":"Gene Ther"},{"issue":"7","key":"2516_CR35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/antibiotics10070828","volume":"10","author":"M Comegna","year":"2021","unstructured":"Comegna M, et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy for cystic fibrosis patients with the F508del\/unknown genotype. Antibiotics (Basel). 2021;10(7):828.","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"2516_CR36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jmoldx.2016.02.007","volume":"18","author":"M Lucarelli","year":"2016","unstructured":"Lucarelli M, et al. the impact on genetic testing of mutational patterns of CFTR gene in different clinical macrocategories of cystic fibrosis. J Mol Diagn. 2016;18(4):554\u201365.","journal-title":"J Mol Diagn"},{"issue":"1","key":"2516_CR37","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41467-022-30668-y","volume":"13","author":"YJ Kim","year":"2022","unstructured":"Kim YJ, et al. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy. Nat Commun. 2022;13(1):2978.","journal-title":"Nat Commun"},{"issue":"1","key":"2516_CR38","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","volume":"13","author":"EJ Sanderlin","year":"2022","unstructured":"Sanderlin EJ, et al. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway. Nat Commun. 2022;13(1):2344.","journal-title":"Nat Commun"},{"issue":"5","key":"2516_CR39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2019.02.009","volume":"18","author":"MA Aksit","year":"2019","unstructured":"Aksit MA, et al. Decreased mRNA and protein stability of W1282X limits response to modulator therapy. J Cyst Fibros. 2019;18(5):606\u201313.","journal-title":"J Cyst Fibros"},{"issue":"21","key":"2516_CR40","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.3390\/ijms222111972","volume":"22","author":"A Venturini","year":"2021","unstructured":"Venturini A, et al. Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene. Int J Mol Sci. 2021;22(21):11972.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2516_CR41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","volume":"19","author":"O Laselva","year":"2020","unstructured":"Laselva O, et al. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action. J Cyst Fibros. 2020;19(5):717\u201327.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2516_CR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","volume":"180","author":"CE Bear","year":"2020","unstructured":"Bear CE. A therapy for most with cystic fibrosis. Cell. 2020;180(2):211.","journal-title":"Cell"},{"issue":"8","key":"2516_CR43","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/genes12081178","volume":"12","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi V, et al. Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in three subjects with the cystic fibrosis genotype Phe508del\/unknown and advanced lung disease. Genes (Basel). 2021;12(8):1178.","journal-title":"Genes (Basel)"},{"issue":"4","key":"2516_CR44","doi-asserted-by":"crossref","first-page":"e1656","DOI":"10.1002\/mgg3.1656","volume":"9","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi V, et al. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol Genet Genom Med. 2021;9(4):e1656.","journal-title":"Mol Genet Genom Med"},{"key":"2516_CR45","doi-asserted-by":"crossref","unstructured":"Amatngalim GD et al. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia. Life Sci Alliance. 2022; 5(12).","DOI":"10.26508\/lsa.202101320"},{"issue":"1","key":"2516_CR46","first-page":"4","volume":"10","author":"J Conti","year":"2022","unstructured":"Conti J, Sorio C, Melotti P. Organoid technology and its role for theratyping applications in cystic fibrosis. Children (Basel). 2022;10(1):4.","journal-title":"Children (Basel)"},{"issue":"4","key":"2516_CR47","doi-asserted-by":"crossref","first-page":"e100300","DOI":"10.15252\/embj.2018100300","volume":"38","author":"N Sachs","year":"2019","unstructured":"Sachs N, et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38(4):e100300.","journal-title":"EMBO J"}],"updated-by":[{"DOI":"10.1186\/s12931-023-02535-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000}}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02516-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:24:44Z","timestamp":1700328284000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2516"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02516-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12931-023-02535-x","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12931-023-02535-x","URL":"https:\/\/doi.org\/10.1186\/s12931-023-02535-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human samples were provided in accordance with the consent procedures approved by the Internal Review Board of Policlinico Umberto I Hospital, Sapienza University of Rome (Ethics committee ref. 5660 prot 983\/19 December 18th 2019 and ref. 6841 prot. 98\/2023 February 8th 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Each patient signed an informed consent form with respect to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}